EPRX Eupraxia Pharmaceuticals Inc.
Company Analysis
Latest News
🔴 Eupraxia Pharmaceuticals is trading 10.14% down today with no clear company-specific catalyst
Eupraxia Pharmaceuticals is trading at $6.82, down 10.14%, with no clear company-specific catalyst identified for the October 23 decline. - Recent company...
🔴 Eupraxia Pharmaceuticals is trading 5.9% down today with healthcare-sector weakness a possible factor
Eupraxia Pharmaceuticals is trading at $7.14, down 5.86%, with no clear company-specific catalyst identified for the October 23 decline. - Recent company news...
🟢 Eupraxia Pharmaceuticals is trading 10.36% up today amid healthcare-led sector rotation
Eupraxia Pharmaceuticals is trading at $7.67, up 10.36%, amid healthcare-sector strength and rotation into defensive stocks, the clearest available market...
🟢 Eupraxia Pharmaceuticals is trading 5% up today amid healthcare's reported 2.12% regular-session gain
Eupraxia Pharmaceuticals is trading at $7.30, up 5.04%, amid a reported healthcare-sector rally, with healthcare up 2.12% in the regular session. - No...
🟢 Eupraxia Pharmaceuticals is trading 15.68% up in pre-market
Eupraxia Pharmaceuticals is trading 15.68% up at $8.04 in pre-market on October 20, 2026, with no confirmed new company announcement directly explaining the...
🟢 Eupraxia Pharmaceuticals is trading 6% up today amid a broader U.S. technology-stock rebound
Eupraxia Pharmaceuticals is trading at $7.01, up 5.89%, alongside a broader rebound in U.S. technology stocks. - The Nasdaq is up 0.96%, and the S&P 500 is up...
🟢 Eupraxia Pharmaceuticals is trading 12.1% up in pre-market amid higher U.S. indices
Eupraxia Pharmaceuticals is trading at $7.42, +12.08% before the October 19 session, with broader risk-on sentiment possibly contributing. - U.S. indices are...
Eupraxia Hits 120-Patient Enrollment Target in RESOLVE Phase 2b Trial
Eupraxia Pharmaceuticals Inc. reached its enrollment target for the placebo-controlled Phase 2b portion of its RESOLVE trial of EP-104GI, an investigational...
🔴 Eupraxia Pharmaceuticals is trading 5% down as no company-specific catalyst is confirmed
Eupraxia Pharmaceuticals is trading at $6.93, down 5.26%, with healthcare-sector weakness a possible contributor. - XLV fell 1.37% during the regular session...
🟢 Eupraxia Pharmaceuticals is trading 7% up in pre-market — no confirmed catalyst identified
Eupraxia Pharmaceuticals is trading at $7.99, up 7.07%, in pre-market; no confirmed catalyst for the move has been identified. - The company is scheduled to...
🟢 Eupraxia Pharmaceuticals is trading 7.1% up in after-hours trading with no confirmed catalyst
Eupraxia Pharmaceuticals is trading at $7.99, up 7.10%, with no specific after-hours catalyst established. - On October 9, Eupraxia Pharmaceuticals announced...
Eupraxia Draws Cantor's $19 Target Reaffirmation, With Over 140% Upside
On October 8, 2026, Cantor Fitzgerald reiterated its Overweight rating on Eupraxia Pharmaceuticals (NASDAQ: EPRX). The firm maintained its $19.00 price target....
🟢 Eupraxia Pharmaceuticals is trading 5.9% up in pre-market
Eupraxia Pharmaceuticals is trading 5.94% up at $8.02 in pre-market; no new company-specific announcement explains the October 9 move. - The October 8 close...
🔴 Eupraxia Pharmaceuticals is trading 5.66% down today amid oil and Treasury-yield concerns
Eupraxia Pharmaceuticals is trading 5.66% down at $7.34 with the market open amid broader oil-price and Treasury-yield concerns. - No clear company-specific...
🔴 Eupraxia Pharmaceuticals is trading 9.9% down in pre-market
Eupraxia Pharmaceuticals is trading 9.9% down at $7.01, with no clear company-specific announcement identified for October 8. - The latest surfaced company...
🟢 Eupraxia Pharmaceuticals is trading 19.4% up in pre-market
Eupraxia Pharmaceuticals is trading 19.4% higher at $9.25 in pre-market on October 6, 2026; no company announcement is listed for October 5 or 6. - Shares...
🟢 Eupraxia Pharmaceuticals is trading 9.75% up in pre-market
Eupraxia Pharmaceuticals is trading at $8.50, up 9.75% in pre-market, with no clear company-specific catalyst identified. - Its latest release, dated...
🟢 Eupraxia Pharmaceuticals is trading 5% up with no clear catalyst identified
Eupraxia Pharmaceuticals is trading at $7.61, up 5.11%, with no clear company-specific catalyst identified for October 5. - The latest listed release is...
🔴 Eupraxia Pharmaceuticals is trading 5% down; no clear catalyst identified
Eupraxia Pharmaceuticals is trading at $7.42, down 5.24%, with no clear company-specific catalyst identified for October 2. - The shares were also down 13.96%...
🔴 Eupraxia Pharmaceuticals is trading 11% down today with no clear company-specific catalyst reported
Eupraxia Pharmaceuticals is trading 10.99% down at $8.10, with no clear company-specific news reported on October 1 explaining the decline. - Shares rose...